ArticleFrontiers in pharmacology2022

Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells.

Weam Othman Elbezanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.